查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2015230

胚胎着床前基因检测市场：2026-2032年全球市场预测（依检测类型、技术类型、交付方式、实施阶段、应用程式和最终用户划分）

Preimplantation Genetic Testing Market by Test Type, Technology Type, Offering, Procedure Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，胚胎着床前基因检测 (PGT) 市值将达到 8.7501 亿美元，到 2026 年将增长至 9.8115 亿美元，到 2032 年将达到 19.7849 亿美元，年复合增长率为 12.36%。

主要市场统计数据
基准年 2025 8.7501亿美元
预计年份：2026年 9.8115亿美元
预测年份 2032 1,978,490,000 美元
复合年增长率 (%) 12.36%

对胚胎着床前基因检测的引人入胜的展望，涵盖临床整合、技术成熟度和不断变化的相关人员期望。

胚胎着床前遗传学检测（PGD）已从辅助生殖技术中的一种特殊辅助工具发展成为生殖遗传学和个人化生殖医学的核心要素。临床医生、检查室管理者和医疗保健领导者现在都认识到，基因检测对于胚胎选择、降低单基因疾病风险以及优化临床结果至关重要。在不断变化的监管预期和保险公司态度的推动下，检查室和诊所面临越来越大的压力，需要确保诊断准确性、简化工作流程，并向患者和转诊网络证明其临床效用。

技术创新、不断发展的临床工作流程和监管改进如何重塑生殖遗传学的检测实践和病患照护路径？

随着临床、技术和监管领域各方力量的融合，胚胎着床前遗传学检测（PGD）领域正经历一场变革。定序精度和生物资讯演算法的进步提高了胚胎遗传评估的分辨率，从而能够更精确地检测非整倍体、结构重排和单基因突变。因此，检查室正从单一方法模式转向结合高通量定序和标靶确认性检测的混合工作流程，从而在应对成本和产能挑战的同时，提高诊断可靠性。

对 2025 年关税变化对诊断和生育服务提供者的供应链、筹资策略和业务永续营运的影响进行系统评估。

2025年关税上调和贸易限制的实施，使得支撑基因检测流程的跨境供应链面临更严格的审查。进口关税和累积关税调整增加了专用设备、试剂和耗材的采购成本，给依赖国际供应商的诊断检查室和生育中心带来了即时的营运压力。为此，许多机构正在重新审视筹资策略，优先选择拥有强大的本地分销网络和替代采购管道的供应商，以减轻关税波动的影响。

将检验类别、调查方法、商业产品和最终用户采用模式与策略重点连结的详细細項分析。

细分市场分析揭示了不同检测类型、形式、技术、产品和服务以及最终用户群体在临床和商业性趋势上的差异。基于检测类型，用于染色体异常检测的 PGT-A、用于单基因疾病检测的 PGT-M 以及用于结构重排检测的 PGT-SR 之间的差异，凸显了检查室工作流程、咨询需求和证据标准方面的不同。例如，PGT-M 计画通常需要针对特定家族开发检测方法，并与临床遗传学深度整合，而 PGT-A 工作流程则优先考虑高通量染色体异常筛检和简化的报告流程。基于检测类型，胚胎着床前遗传学诊断 (PGD) 和胚胎着床前遗传学筛检(PGS) 之间的区别，凸显了临床目标和患者咨询方面的差异。诊断通常着重于已知的遗传性变异和针对性解读，而筛检强调更广泛的染色体评估和人群层面的风险分层。

区域法规结构、支付方环境和临床部署模式如何塑造美洲、欧洲、中东和非洲以及亚太地区的差异化策略。

区域趋势正在影响胚胎着床前遗传学检测 (PGD) 领域的服务提供模式和策略伙伴关係。在美洲，主要都市区的先进临床部署与透过私人生育网络快速传播的创新技术并存，从而形成了一个由专业检测实验室、转诊诊所和学术合作机构组成的密集生态系统。相较之下，欧洲、中东和非洲的法规结构和支付模式则更为多样化。高度先进的公立和私立中心分布分散，而服务取得受限的地区也并存，这导致了跨境病患流动和集中式检测服务的出现。这种区域差异正在推动更广泛的检测网络和标准化报告方法的发展，以满足跨辖区的临床需求。

企业策略与伙伴关係趋势揭示了整合、专业化和协作如何重新定义诊断和服务供应商的竞争优势

胚胎着床前遗传学检测 (PGD) 领域的企业级趋势反映了垂直整合、策略专业化和协作生态系统的整合。一些机构专注于提供端到端解决方案，整合仪器、试剂和分析软体，为生育诊所和中心检查室提供承包解决方案。而其他机构则专注于自身优势领域，例如开发罕见单基因疾病检测、高解析度结构变异检测或用于变异解读和报告的云原生分析技术。同时，检测服务供应商正在拓展临床伙伴关係和转诊网络，以提供具有标准化品管和整合报告框架的外包检测服务。

产业相关人员可以实施切实可行的策略，以增强证据产生、供应链韧性、资讯学整合和以病人为中心的服务提供。

产业领导者可以采取果断措施来提升临床相关性、业务永续营运和商业性差异化。首先，他们应优先投资于检测方法检验和临床证据，以证明产品在不同患者群体和临床路径中的真实效用。这些证据将推动临床医生采纳产品，并更有效地向支付方和医疗采购负责人传达产品价值。其次，他们应透过多元化采购、与区域分销商建立合作关係以及製定库存策略来建立具有韧性的供应链，从而降低关税和地缘政治动盪带来的风险。透过强调透明的总拥有成本和可预测的补货，企业可以减少服务中断并保障利润率。

透明严谨的调查方法，结合专家的直接访谈、第二手资料的整合以及反覆检验，确保了可靠且可操作的见解。

本分析的调查方法结合了对专家的深入访谈以及对第二手资料的系统整合和反覆检验。深入研究包括对临床检查室管理人员、胚胎学家、遗传咨询师、采购负责人和监管专家进行详细访谈，以了解实际操作、临床决策因素和采购限制。这些质性研究结果辅以对主流检测方法、分析表现特征和工作流程整合挑战的技术评估，并透过引用同行评审文献和技术白皮书来确保方法论的严谨性。

策略、营运和临床促进因素的明确整合，将决定基因检测在生殖医学中的持续引入和长期整合。

总之，胚胎着床前遗传学检测（PGD）正处于一个转折点，技术成熟度、患者期望和实际情况在此交汇，重塑着服务的提供方式。实验室和生育服务机构必须平衡高分析效能、可扩展的工作流程和稳健的供应链。不断变化的法规环境和支付方的严格审查将使那些优先考虑严格检验、清晰的临床证据和可证明的品管的机构受益。同时，对生物资讯学、解读软体和整合咨询路径的投资将在提供以患者为中心的护理和支持临床医生采用PGD方面发挥关键作用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章胚胎着床前基因检测市场：检测类型

  • PGT-A（染色体异常）
  • PGT-M（原发性腺组织疾病）
  • PGT-SR（结构重建）
  • PGT-HLA（人类白血球抗原（HLA）相容性检测）

第九章胚胎着床前基因检测市场：依技术类型划分

  • 比较基因杂合反应
  • 萤光原位杂合反应
  • 次世代定序
  • 基于PCR的检测
  • 单核苷酸多态性

第十章：胚胎着床前基因检测市场：依产品/服务分类

  • 装置
  • 试剂和耗材
    • 成套工具
    • 探测

第十一章 依治疗阶段胚胎着床前基因检测市场

  • 切片检查
  • 极切片检查
  • 胚囊切片

第十二章胚胎着床前基因检测市场：依应用领域划分

  • 染色体数目异常筛检
  • 单基因疾病
  • 体外受精（IVF）的预后

第十三章胚胎着床前基因检测市场：依最终用户划分

  • 诊断检测实验室
  • 不孕症治疗诊所
  • 医院
  • 研究机构

第十四章胚胎着床前基因检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章胚胎着床前基因检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章胚胎着床前基因检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国胚胎着床前基因检测市场

第十八章：中国胚胎着床前基因检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Techne Corporation
  • Bioarray SL
  • EUROPE IVF International sro
  • F. Hoffmann-La Roche AG
  • Genea Limited
  • GENETiKS
  • Illumina, Inc.
  • Invicta Genetics
  • Invitae Corporation
  • Juno Genetics, US Inc.
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Merck KGaA
  • Natera, Inc.
  • NextGen Genetics Holdings, LLC
  • Ovation Fertility
  • PacGenomics
  • PerkinElmer, Inc.
  • Progyny, Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations, LLC
  • SEQUENCE46, LLC
  • Sysmex Corporation
  • Takara Bio Inc.
  • The Cooper Companies Inc.
  • Thermo Fisher Scientific Inc.
  • Vitrolife Sweden AB
  • Yikon Genomics（Shanghai）Co., Ltd.
Product Code: MRR-030EE48515DA

The Preimplantation Genetic Testing Market was valued at USD 875.01 million in 2025 and is projected to grow to USD 981.15 million in 2026, with a CAGR of 12.36%, reaching USD 1,978.49 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 875.01 million
Estimated Year [2026] USD 981.15 million
Forecast Year [2032] USD 1,978.49 million
CAGR (%) 12.36%

A compelling orientation to preimplantation genetic testing that frames clinical integration, technological maturation, and evolving stakeholder expectations

Preimplantation genetic testing has moved from a specialized adjunct to assisted reproduction into a core element of reproductive genetics and personalized reproductive care. Clinicians, laboratory directors, and institutional leaders now evaluate genetic testing as an integral part of embryo selection, risk mitigation for monogenic disorders, and optimizing clinical outcomes. Against a backdrop of evolving regulatory expectations and shifting payer attitudes, laboratories and clinics face heightened pressure to ensure diagnostic accuracy, streamline workflows, and demonstrate clinical utility to both patients and referral networks.

Technological progress has compressed turnaround times and improved resolution, enabling more definitive clinical decision-making while opening new pathways for integration with bioinformatics and electronic health records. Concurrently, patient expectations around transparency, counseling, and access are reshaping service delivery models; patients increasingly demand clear explanations of test scope, limitations, and the downstream implications for reproductive choices. As a result, cross-functional collaboration among embryologists, genetic counselors, laboratory scientists, and informatics specialists has become essential for delivering clinically robust and ethically sound testing programs.

Looking ahead, stakeholder imperatives center on harmonizing clinical evidence with operational scalability. Laboratories and fertility providers must reconcile the need for high-throughput, reproducible assays with individualized patient care. At the same time, research institutions and diagnostic partners are expanding translational efforts to refine variant interpretation, validate novel assays, and expand testing indications. This introduction sets the stage for a deeper appraisal of the transformative shifts reshaping the preimplantation genetic testing landscape.

How converging technological innovations, evolving clinical workflows, and regulatory refinements are reshaping testing operations and patient pathways in reproductive genetics

The preimplantation genetic testing environment is undergoing transformative shifts driven by converging clinical, technological, and regulatory forces. Advances in sequencing accuracy and bioinformatic algorithms have increased the resolution of embryo genetic assessment, enabling more nuanced detection of aneuploidy, structural rearrangements, and single-gene variants. Consequently, laboratories are transitioning from single-method paradigms to hybrid workflows that combine high-throughput sequencing with targeted confirmatory assays, thereby improving diagnostic confidence while managing cost and throughput considerations.

Simultaneously, the clinical ecosystem is adapting to greater patient demand for comprehensive genetic insight coupled with clear counseling frameworks. Genetic counseling has become more central to the patient journey, facilitating informed decision-making and risk communication. In parallel, payers and health systems are beginning to scrutinize clinical value propositions more closely, which is prompting providers to collect outcomes data and demonstrate the real-world utility of testing strategies. Regulatory authorities are also refining oversight, with increased expectations for analytical and clinical validation, laboratory accreditation, and post-market surveillance of diagnostic assays.

Operationally, supply chain resilience and reagent standardization have moved to the forefront of laboratory planning, prompting investments in inventory management and diversified sourcing. At a higher level, strategic alliances between fertility clinics, diagnostic laboratories, and specialist software providers are accelerating to create vertically integrated solutions that combine laboratory services with analytics, reporting, and patient engagement. These transformative shifts are collectively reshaping how testing is delivered, reimbursed, and perceived by patients and clinicians alike.

Assessing the systemic consequences of 2025 tariff changes on supply chains, procurement strategies, and operational resilience across diagnostic and fertility providers

The introduction of elevated tariff measures and trade restrictions in 2025 has intensified scrutiny of cross-border supply chains that support genetic testing workflows. Import levies and cumulative tariff adjustments have increased landed costs for specialized instruments, reagents, and consumables, creating immediate operational pressure for diagnostic laboratories and fertility centers that depend on international suppliers. In response, many organizations have re-evaluated procurement strategies to prioritize suppliers with robust local distribution networks or alternative sourcing channels that mitigate exposure to tariff volatility.

These trade dynamics have cascading implications for capital investment and service delivery. Institutions contemplating new instrument acquisitions are weighing not only acquisition price but also long-term maintenance, spare parts availability, and reagent procurement risk. As a result, procurement cycles have elongated and capital allocation decisions have been re-prioritized to favor suppliers with transparent total cost of ownership and resilient logistics. Some providers have also accelerated efforts to aggregate purchasing across regional networks or enter into long-term supply agreements to stabilize pricing and availability.

Beyond procurement, tariffs have spurred renewed interest in nearshoring and regional manufacturing partnerships. Stakeholders are evaluating opportunities to localize component assembly or reagent production to reduce exposure to import duties and expedite replenishment lead times. At the same time, laboratories are investing in process optimization and assay robustness to reduce dependency on single-source reagents. In short, the cumulative impact of tariff changes in 2025 has heightened emphasis on supply chain agility, local partnership development, and procurement governance as fundamental elements of operational resilience.

In-depth segmentation insights that connect testing categories, methodological platforms, commercial offerings, and end-user adoption patterns to strategic priorities

Segmentation analysis reveals differentiated clinical and commercial dynamics across testing types, test formats, technologies, offerings, and end users. Based on testing type, distinctions among PGT-A for aneuploidy detection, PGT-M for monogenic disorders, and PGT-SR for structural rearrangements highlight divergent laboratory workflows, counseling needs, and evidentiary standards; for example, PGT-M programs often require intensive family-specific assay development and deep clinical-genetic integration, whereas PGT-A workflows prioritize high-throughput aneuploidy screening and streamlined reporting. Based on test type, the separation between preimplantation genetic diagnosis and preimplantation genetic screening underscores differences in clinical intent and patient counseling; diagnosis is typically focused on known familial variants and targeted interpretation, while screening emphasizes broader chromosomal assessment and population-level risk stratification.

Based on technology type, the competitive dynamics hinge on methodological trade-offs among comparative genomic hybridization, fluorescent in-situ hybridization, next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism arrays. Next-generation sequencing is increasingly favored for its scalability and resolution, yet PCR-based and SNP approaches retain roles in confirmatory testing and specific assay designs. Comparative genomic hybridization and FISH continue to be relevant for certain structural assessments and regulatory-validated workflows, especially where orthogonal confirmation is required. Based on offering, the ecosystem separates into instruments, reagents and consumables, and software; instruments drive capital expenditure and laboratory footprint decisions, reagents and consumables determine recurring operating costs and supply chain exposure, and software governs data interpretation, reporting, and integration with clinical systems. Based on end user, diagnostic laboratories, fertility clinics, hospitals, and research institutes exhibit variable adoption patterns; diagnostic laboratories prioritize standardized, high-throughput workflows and accreditation, fertility clinics focus on turnaround time and counseling integration, hospitals emphasize interdisciplinary coordination and inpatient pathways, and research institutes prioritize methodological innovation and validation pathways. Together, these segmentation lenses illuminate where clinical needs, operational constraints, and commercial opportunities intersect, enabling stakeholders to prioritize investments and partnerships aligned with their strategic capabilities.

How regional regulatory frameworks, payer environments, and clinical adoption patterns are shaping differentiated strategies in the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape both service delivery models and strategic partnerships across the preimplantation genetic testing landscape. Americas maintain a combination of advanced clinical adoption in major urban centers and rapid innovation diffusion through private fertility networks, which has led to a dense ecosystem of specialized laboratories, referral clinics, and academic collaborators. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer models; pockets of highly advanced public and private centers coexist with regions where access is constrained, driving cross-border patient mobility and centralized laboratory services. This regional heterogeneity encourages pan-regional laboratory networks and standardized reporting approaches to address cross-jurisdictional clinical needs.

Asia-Pacific exhibits heterogenous trajectories as well, with select markets demonstrating rapid scale-up of assisted reproductive services, strong private-sector investment, and increased local capability in genomics. At the same time, several markets in the region are investing in capacity-building and regulatory frameworks to support clinical validation and ethical oversight. Across all regions, differences in reimbursement landscapes, regulatory expectations, and cultural perspectives on reproductive genetics influence service models, patient counseling practices, and commercialization strategies. As a result, successful regional approaches blend localized clinical pathways with global best practices in quality management and evidence generation, enabling providers to deliver consistent, ethically grounded, and operationally sustainable testing services.

Corporate strategies and partnership dynamics revealing how integration, specialization, and collaboration are redefining competitive advantage across diagnostics and service providers

Company-level dynamics in the preimplantation genetic testing space reflect a mix of vertical integration, strategic specialization, and collaborative ecosystems. Some organizations have concentrated on end-to-end solutions that combine instrumentation, reagents, and interpretive software to deliver turnkey offerings for fertility clinics and centralized laboratories. Other players have focused on niche strengths such as assay development for rare monogenic disorders, high-resolution structural variant detection, or cloud-native analytics for variant interpretation and reporting. In parallel, laboratory service providers have expanded clinical partnerships and referral networks to offer outsourced testing with standardized quality controls and consolidated reporting frameworks.

Partnerships and alliance formation have emerged as a primary vector for capability expansion. Commercial agreements between diagnostic laboratories and fertility networks, as well as collaborations with software vendors for integrated reporting, have enabled faster market entry and reduced the need for duplicative capital investment. In addition, strategic investments in regulatory compliance and accreditation have become competitive differentiators for laboratories seeking to serve international referral markets. Mergers and acquisitions continue to reconfigure the competitive terrain, especially where scale affords supply chain leverage, broader test menus, and enhanced data assets for variant curation. Collectively, these company insights underscore the importance of aligning technical capabilities with clear commercial pathways and compliance infrastructure to sustain growth and clinical credibility.

Practical, high-impact strategies that industry stakeholders can implement to enhance evidence generation, supply chain resilience, informatics integration, and patient-centered service delivery

Industry leaders can take decisive actions to strengthen clinical relevance, operational resilience, and commercial differentiation. First, prioritize investment in assay validation and clinical evidence that demonstrate real-world utility across diverse patient cohorts and clinical pathways; such evidence supports stronger clinician adoption and more effective communication of value to payers and institutional buyers. Second, cultivate resilient supply chains through multi-source procurement, regional distributor partnerships, and inventory strategies that mitigate exposure to tariff-driven or geopolitical disruptions. By emphasizing transparent total cost of ownership and predictable replenishment, organizations can reduce service interruptions and protect margins.

Third, accelerate integration of robust bioinformatics and interpretive software to standardize reporting, improve turnaround time, and enhance variant curation workflows. Interoperability with electronic health records and laboratory information systems will be a significant factor in clinician acceptance and cross-disciplinary coordination. Fourth, embed genetic counseling into the patient pathway to ensure informed consent, appropriate expectation-setting, and patient-centered communication about test scope and limitations. Finally, pursue strategic alliances and partnership models that combine clinical expertise, laboratory scale, and data analytics to unlock synergies while preserving regulatory compliance. These actions, when implemented in concert, create a defensible position that addresses both near-term operational risks and longer-term strategic growth.

Transparent and rigorous research methodology combining primary expert interviews, secondary evidence synthesis, and iterative validation to ensure robust and actionable insights

The research methodology underpinning this analysis blends primary expert engagement with structured secondary synthesis and iterative validation. Primary research included in-depth interviews with clinical laboratory leaders, embryologists, genetic counselors, procurement officers, and regulatory specialists to capture operational realities, clinical decision drivers, and procurement constraints. These qualitative insights were complemented by technical assessments of prevailing assay methodologies, analytical performance characteristics, and workflow integration challenges, drawing on peer-reviewed literature and technical white papers to ensure methodological rigor.

Secondary synthesis involved systematic review of clinical guidelines, professional society statements, and regulatory advisories to align the analysis with current standards of practice and compliance expectations. Data triangulation was used to reconcile divergent inputs and to surface consistent patterns across respondent groups and documented sources. Finally, findings underwent internal peer review and scenario stress-testing to evaluate sensitivity to supply chain disruptions, tariff variations, and technology adoption trajectories. The combined methodology ensures that conclusions are grounded in both frontline operational experience and documented best practices, providing a reliable basis for decision-making and strategic planning.

A definitive synthesis of the strategic imperatives, operational challenges, and clinical enablers that will determine sustainable adoption and long-term integration of genetic testing in reproductive care

In synthesis, preimplantation genetic testing stands at an inflection point where technological maturation, patient expectations, and operational realities converge to reshape service delivery. Laboratories and fertility providers must balance the need for high analytical performance with scalable workflows and resilient supply chains. The evolving regulatory environment and payer scrutiny will reward organizations that prioritize rigorous validation, clear clinical evidence, and demonstrable quality controls. At the same time, investments in bioinformatics, interpretive software, and integrated counseling pathways will be decisive in delivering patient-centered care and supporting clinician adoption.

Strategically, stakeholders that pursue collaborative models-combining laboratory excellence, clinical partnerships, and software-enabled reporting-are best positioned to translate technical capability into sustainable clinical services. Moreover, pragmatic procurement and regional partnership strategies will mitigate exposure to trade disruptions and tariff-related cost pressures. Looking forward, the sector's ability to standardize quality metrics, improve variant interpretation, and communicate clinical utility effectively will determine its broader acceptance and long-term integration into reproductive health practice. These conclusions underscore the imperative for coordinated action across clinical, operational, and commercial domains to realize the full potential of preimplantation genetic testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preimplantation Genetic Testing Market, by Test Type

  • 8.1. PGT-A (Aneuploidy)
  • 8.2. PGT-M (Monogenic Disorders)
  • 8.3. PGT-SR (Structural Rearrangements)
  • 8.4. PGT-HLA (Human Leukocyte Antigen Matching)

9. Preimplantation Genetic Testing Market, by Technology Type

  • 9.1. Comparative Genomic Hybridization
  • 9.2. Fluorescent In-Situ Hybridization
  • 9.3. Next-Generation Sequencing
  • 9.4. PCR-Based Testing
  • 9.5. Single-Nucleotide Polymorphism

10. Preimplantation Genetic Testing Market, by Offering

  • 10.1. Instruments
  • 10.2. Reagents & Consumables
    • 10.2.1. Kits
    • 10.2.2. Probes

11. Preimplantation Genetic Testing Market, by Procedure Stage

  • 11.1. Embryo Biopsy
  • 11.2. Polar Body Biopsy
  • 11.3. Blastocyst Biopsy

12. Preimplantation Genetic Testing Market, by Application

  • 12.1. Aneuploidy Screening
  • 12.2. Monogenic Diseases
  • 12.3. IVF Prognosis

13. Preimplantation Genetic Testing Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Fertility Clinics
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Preimplantation Genetic Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Preimplantation Genetic Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Preimplantation Genetic Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Preimplantation Genetic Testing Market

18. China Preimplantation Genetic Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Bio-Techne Corporation
  • 19.8. Bioarray S.L.
  • 19.9. EUROPE IVF International s.r.o.
  • 19.10. F. Hoffmann-La Roche AG
  • 19.11. Genea Limited
  • 19.12. GENETiKS
  • 19.13. Illumina, Inc.
  • 19.14. Invicta Genetics
  • 19.15. Invitae Corporation
  • 19.16. Juno Genetics, US Inc.
  • 19.17. Laboratory Corporation of America Holdings
  • 19.18. MedGenome Labs Ltd.
  • 19.19. Merck KGaA
  • 19.20. Natera, Inc.
  • 19.21. NextGen Genetics Holdings, LLC
  • 19.22. Ovation Fertility
  • 19.23. PacGenomics
  • 19.24. PerkinElmer, Inc.
  • 19.25. Progyny, Inc.
  • 19.26. Qiagen N.V.
  • 19.27. Quest Diagnostics Incorporated
  • 19.28. Reproductive Genetic Innovations, LLC
  • 19.29. SEQUENCE46, LLC
  • 19.30. Sysmex Corporation
  • 19.31. Takara Bio Inc.
  • 19.32. The Cooper Companies Inc.
  • 19.33. Thermo Fisher Scientific Inc.
  • 19.34. Vitrolife Sweden AB
  • 19.35. Yikon Genomics (Shanghai) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY EMBRYO BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY EMBRYO BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY EMBRYO BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLAR BODY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLAR BODY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLAR BODY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY BLASTOCYST BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY BLASTOCYST BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY BLASTOCYST BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY IVF PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY IVF PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY IVF PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 180. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 181. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 188. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 189. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)